A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues

Cunningham, David; Bradley, Cathy J.; Forrest, G J; Hutcheon, A. W.; Adams, Lynn; Sneddon, Margaret; Harding, M.; Kerr, D. J.; Soukop, M.; Kaye, SB

doi:10.1016/0277-5379(88)90300-8

Cited by 49 publications

(26 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In cancer patients, administration of oral Δ 9 -THC has been shown to significantly suppress the experience of nausea and vomiting, in comparison to placebo controls (Chang et al, 1979; Frytak et al, 1979; Orr et al, 1980; Sallan et al, 1975; Sweet et al, 1981) and when compared to the D 2 receptor antagonists available at the time, Δ 9 -THC was at least as effective (Carey et al, 1983; Crawford and Buckman, 1986; Cunningham et al, 1988; Frytak et al, 1979; Tramèr et al, 2001; Ungerleider et al, 1984) if not more effective (Ekert et al, 1979; Orr and McKernan, 1981) at reducing nausea and vomiting. Clinical evidence suggests that Δ 8 -THC suppresses anticipatory nausea in child patients (Abrahamov et al, 1995).…”

Section: Cannabinoids and Endocannabinoids In The Control Of Nausementioning

confidence: 99%

Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system

Sharkey

Darmani

Parker

2014

European Journal of Pharmacology

168

136

View full text Add to dashboard Cite

Nausea and vomiting (emesis) are important elements in defensive or protective responses that animals use to avoid ingestion or digestion of potentially harmful substances. However, these neurally-mediated responses are at times manifested as symptoms of disease and they are frequently observed as side-effects of a variety of medications, notably those used to treat cancer. Cannabis has long been known to limit or prevent nausea and vomiting from a variety of causes. This has led to extensive investigations that have revealed an important role for cannabinoids and their receptors in the regulation of nausea and emesis. With the discovery of the endocannabinoid system, novel ways to regulate both nausea and vomiting have been discovered that involve the production of endogenous cannabinoids acting centrally. Here we review recent progress in understanding the regulation of nausea and vomiting by cannabinoids and the endocannabinoid system, and we discuss the potential to utilize the endocannabinoid system in the treatment of these frequently debilitating conditions.

show abstract

Section: Cannabinoids and Endocannabinoids In The Control Of Nausementioning

confidence: 99%

Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system

Sharkey

Darmani

Parker

2014

European Journal of Pharmacology

168

136

View full text Add to dashboard Cite

show abstract

“…Prochlorperazine is also effective, after intravenous administration, in the rapid control of vomiting in the emergency department [8]. Furthermore, several antiemetic preparations contain prochlorperazine in association with granisetron, dexamethason, lorazepam, scopolamine, or nabilone [9][10][11][12]. Another therapeutic use of prochlorperazine is the relief of migraine attacks.…”

Section: Introductionmentioning

confidence: 99%

Prochlorperazine induces central antinociception mediated by the muscarinic system

Ghelardini

Galeotti

Uslenghi

et al. 2004

Pharmacological Research

View full text Add to dashboard Cite

The antinociceptive effect of the D 2 antagonist prochlorperazine was examined in the mouse hot-plate and abdominal constriction tests. Prochlorperazine (1-2 mg kg −1 s.c./i.p.) produced an increase of the pain threshold in the mouse hot-plate test. The antinociception produced by prochlorperazine was prevented by the D 2 selective agonist quinpirole, the unselective muscarinic antagonist atropine, the M 1 selective antagonist pirenzepine, and by the choline uptake inhibitor hemicholinium-3 hydrobromide (HC-3). Moreover, prochlorperazine antinociception was abolished by pretreatment with an aODN against the M 1 receptor subtype, administered at the dose of 2 nmol per single i.c.v. injection. By contrast the analgesic effect of prochlorperazine was not prevented by the opioid antagonist naloxone and the GABA B antagonist CGP-35348. Prochlorperazine also elicited a dose-dependent increase in ACh release from rat cerebral cortex. In the antinociceptive dose-range, prochlorperazine did not impair mouse performance evaluated by the rota-rod and hole-board tests. On the basis of the above data, it can be postulated that prochlorperazine exerted an antinociceptive effect mediated by a central cholinergic mechanism.

show abstract

“…Among them, Silibinin which is currently under phase III clinical trials for hepatitis C virus infection therapy had drawn more attentions. In the 2D fingerprint similarity measurements above, Silibinin was found to possess similar chemical features not only to the following approved drugs: Nabilone which is used for control of nausea and vomiting caused by chemotherapeutic agents in the treatment of cancer [43–45], Hesperetin, that is, a cholesterol-lowering flavanoid with antioxidant, anti-inflammatory and anticarcinogenic activities [46–48], and Propafenone which is used in the treatment of atrial and ventricular arrhythmias [49, 50], but also to the withdrawn drug Plicamycin, that is, an antineoplastic antibiotic but has been withdrawn for a dose-related bleeding syndrome [51–53]. …”

Section: Resultsmentioning

confidence: 99%

Predicting the Drug Safety for Traditional Chinese Medicine through a Comparative Analysis of Withdrawn Drugs Using Pharmacological Network

Xue

Zhang

Cai

et al. 2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

As the major issue to limit the use of drugs, drug safety leads to the attrition or failure in clinical trials of drugs. Therefore, it would be more efficient to minimize therapeutic risks if it could be predicted before large-scale clinical trials. Here, we integrated a network topology analysis with cheminformatics measurements on drug information from the DrugBank database to detect the discrepancies between approved drugs and withdrawn drugs and give drug safety indications. Thus, 47 approved drugs were unfolded with higher similarity measurements to withdrawn ones by the same target and confirmed to be already withdrawn or discontinued in certain countries or regions in subsequent investigations. Accordingly, with the 2D chemical fingerprint similarity calculation as a medium, the method was applied to predict pharmacovigilance for natural products from an in-house traditional Chinese medicine (TCM) database. Among them, Silibinin was highlighted for the high similarity to the withdrawn drug Plicamycin although it was regarded as a promising drug candidate with a lower toxicity in existing reports. In summary, the network approach integrated with cheminformatics could provide drug safety indications effectively, especially for compounds with unknown targets or mechanisms like natural products. It would be helpful for drug safety surveillance in all phases of drug development.

show abstract

A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues

Cited by 49 publications

References 8 publications

Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system

Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system

Prochlorperazine induces central antinociception mediated by the muscarinic system

Predicting the Drug Safety for Traditional Chinese Medicine through a Comparative Analysis of Withdrawn Drugs Using Pharmacological Network

Contact Info

Product

Resources

About